Pharmaceutical Scientist

YUNSHAN CHIANG APT **, **** Bayard Street, Pittsburgh, PA.

412-***-**** adb2hc@r.postjobfree.com

• Multidisciplinary research background involving topical product development.

• Experienced in preclinical pharmaceutical formulation development following good laboratory practices (GLP).

• Developed a vaginal non-hormonal contraceptive film.

Education

University of Pittsburgh. GPA 3.29 Anticipated April 2020

Master of Science, Pharmaceutical Science,

Taipei Medical University. GPA 3.92 June 2018

Bachelor of Science, Medical Laboratory Science and Biotechnology,

Skills __

• HPLC • Drug formulation • Solid phase extraction

• Cell culture • GraphPad Prism • Empower analysis

• SDS-PAGE • RT-PCR • Karl Fischer titrator

• Chromatography • Knowledge of FDA regulations

Work experience

Graduate Research Student

Pharmaceutic Core, University of Pittsburgh- Pittsburgh, PA 2018-2020

Advisor: Dr. Lisa C. Rohan, University of Pittsburgh, PA

• Develop and validate various quantification methods and formulation assessments.

• Work under a NICH Funded project to develop a non-hormonal vaginal film contraceptive.

• Work in GLP certified lab and experience with project time management.

• Experience with HPLC, Solid-phase extraction, dissolution, and stability studies.

• Perform VK2/E5E6 cellular toxicity study.

• Experience with film characterization evaluation (texture analyzer, Karl Fischer and tensiometer)

• Work on pre-clinical drug dissolution modification studies.

Clinical Medical Technologist Intern

Cathay General Hospital-Taipei, Taiwan. Aug-Dec 2017

• Monitored the concentration of Tacrolimus and Cyclosporine in transplant patients.

• Performed radioimmunoassay for hypo-/hyperthyroid patients.

• Collected blood samples from patients.

Undergraduate Research Student 2015-2017

Advisor: Dr. Chia-Hwa Lee, Taipei Medical University, Taiwan.

• Research on Tumor biology in gene therapy.

• Obtained a scholarship from the Ministry of Science and Technology.

• “The lentivirus-mediated ABL CRISPR/Cas9 genome editing sufficiently removed K562 tumorigenicity in vitro and in vivo of a systemic human leukemia animal model.” is under revision to publish in Cancers, 2020.

Contact this candidate